<?xml version="1.0" encoding="ISO-8859-1"?>
<!DOCTYPE ichicsr SYSTEM "http://www.accessdata.fda.gov/xml/icsr-xml-v2.1.dtd">
<ichicsr lang="en">
	<ichicsrmessageheader>
		<messagetype>ichicsr</messagetype>
		<messageformatversion>2.1</messageformatversion>
		<messageformatrelease>2.0</messageformatrelease>
		<messagenumb>4053229_286</messagenumb>
		<messagesenderidentifier>NovartisPH</messagesenderidentifier>
		<messagereceiveridentifier>ZZFDA</messagereceiveridentifier>
		<messagedateformat>204</messagedateformat>
		<messagedate>20121211134654</messagedate>
	</ichicsrmessageheader>
	<safetyreport>
		<safetyreportversion>2</safetyreportversion>
		<safetyreportid>PHHO2012CN017597</safetyreportid>
		<primarysourcecountry>CN</primarysourcecountry>
		<occurcountry>CN</occurcountry>
		<transmissiondateformat>102</transmissiondateformat>
		<transmissiondate>20121211</transmissiondate>
		<reporttype>2</reporttype>
		<serious>1</serious>
		<seriousnessdeath>1</seriousnessdeath>
		<seriousnesslifethreatening>2</seriousnesslifethreatening>
		<seriousnesshospitalization>2</seriousnesshospitalization>
		<seriousnessdisabling>2</seriousnessdisabling>
		<seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
		<seriousnessother>2</seriousnessother>
		<receivedateformat>102</receivedateformat>
		<receivedate>20121207</receivedate>
		<receiptdateformat>102</receiptdateformat>
		<receiptdate>20121210</receiptdate>
		<additionaldocument>2</additionaldocument>
		<fulfillexpeditecriteria>1</fulfillexpeditecriteria>
		<companynumb>PHHO2012CN017597</companynumb>
		<medicallyconfirm>1</medicallyconfirm>
		<primarysource>
			<reportertitle>Dr.</reportertitle>
			<reportergivename>Wang</reportergivename>
			<reporterfamilyname>Jin Wan</reporterfamilyname>
			<reporterorganization>Cancer Institute &amp; Hospital, Chinese Academy of Medical Scie</reporterorganization>
			<reporterstreet>No. 17 Pan-Jia-Yuan Rd, Chao Yang District</reporterstreet>
			<reportercity>Beijing</reportercity>
			<reporterpostcode>100021</reporterpostcode>
			<reportercountry>CN</reportercountry>
			<qualification>1</qualification>
			<sponsorstudynumb>CRAD001L2404</sponsorstudynumb>
			<observestudytype>1</observestudytype>
		</primarysource>
		<primarysource>
			<reportertitle>Dr.</reportertitle>
			<reportergivename>Yang</reportergivename>
			<reporterfamilyname>Lin</reporterfamilyname>
			<reporterorganization>Cancer Institute &amp; Hospital, Chinese Academy of Medical Scie</reporterorganization>
			<reporterstreet>No. 17 Pan-Jia-Yuan Rd, Chao Yang District</reporterstreet>
			<reportercity>Beijing</reportercity>
			<reporterpostcode>100021</reporterpostcode>
			<reportercountry>CN</reportercountry>
			<qualification>1</qualification>
			<observestudytype>1</observestudytype>
		</primarysource>
		<sender>
			<sendertype>1</sendertype>
			<senderorganization>NOVARTIS PHARMACEUTICAL CORPORATION</senderorganization>
			<senderdepartment>Clinical Safety and Epidemiology</senderdepartment>
			<senderfamilyname>Clinical Safety and Epidemiology</senderfamilyname>
			<senderstreetaddress>Novartis Pharmaceuticals Corp. Bldg 419, One Health Plaza</senderstreetaddress>
			<sendercity>East Hanover</sendercity>
			<senderstate>NJ</senderstate>
			<senderpostcode>07936</senderpostcode>
			<sendercountrycode>US</sendercountrycode>
			<sendertel>+1800378</sendertel>
			<sendertelextension>8567</sendertelextension>
			<sendertelcountrycode>US</sendertelcountrycode>
			<senderfax>+1973781</senderfax>
			<senderfaxextension>8001</senderfaxextension>
			<senderfaxcountrycode>US</senderfaxcountrycode>
			<senderemailaddress>gdss.configuration@pharma.novartis.com</senderemailaddress>
		</sender>
		<receiver>
			<receivertype>2</receivertype>
			<receiverorganization>ZZFDA</receiverorganization>
			<receiverdepartment>FDA</receiverdepartment>
			<receivertitle>Mr</receivertitle>
			<receivergivename>William</receivergivename>
			<receiverfamilyname>Taylor</receiverfamilyname>
			<receiverstreetaddress>5600 Fishers Lane Room 16B-45</receiverstreetaddress>
			<receivercity>Rockville</receivercity>
			<receiverstate>MD</receiverstate>
			<receiverpostcode>20857</receiverpostcode>
			<receivercountrycode>US</receivercountrycode>
			<receivertel>+1301827</receivertel>
			<receivertelextension>0964</receivertelextension>
			<receivertelcountrycode>US</receivertelcountrycode>
			<receiverfax>+1301594</receiverfax>
			<receiverfaxextension>0829</receiverfaxextension>
			<receiverfaxcountrycode>US</receiverfaxcountrycode>
			<receiveremailaddress>.</receiveremailaddress>
		</receiver>
		<patient>
			<patientinitial>MHZ</patientinitial>
			<patientinvestigationnumb>20006</patientinvestigationnumb>
			<patientbirthdateformat>102</patientbirthdateformat>
			<patientbirthdate>19420706</patientbirthdate>
			<patientweight>58</patientweight>
			<patientheight>146</patientheight>
			<patientsex>2</patientsex>
			<patientdeath>
				<patientdeathdateformat>102</patientdeathdateformat>
				<patientdeathdate>20121126</patientdeathdate>
				<patientautopsyyesno>3</patientautopsyyesno>
				<patientdeathcause>
					<patientdeathreportmeddraversion>15.1</patientdeathreportmeddraversion>
					<patientdeathreport>Disease progression</patientdeathreport>
				</patientdeathcause>
			</patientdeath>
			<reaction>
				<primarysourcereaction>Death/Progression of study indication</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Disease progression</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Disease progression</reactionmeddrapt>
				<termhighlighted>3</termhighlighted>
				<reactionstartdateformat>102</reactionstartdateformat>
				<reactionstartdate>20121126</reactionstartdate>
				<reactionfirsttime>77</reactionfirsttime>
				<reactionfirsttimeunit>804</reactionfirsttimeunit>
				<reactionlasttime>19</reactionlasttime>
				<reactionlasttimeunit>804</reactionlasttimeunit>
				<reactionoutcome>5</reactionoutcome>
			</reaction>
			<drug>
				<drugcharacterization>1</drugcharacterization>
				<medicinalproduct>AFINITOR </medicinalproduct>
				<obtaindrugcountry>CN</obtaindrugcountry>
				<drugauthorizationnumb>22-334</drugauthorizationnumb>
				<drugauthorizationcountry>CN</drugauthorizationcountry>
				<drugauthorizationholder>NOVARTIS SECTOR: PHARMA</drugauthorizationholder>
				<drugstructuredosagenumb>10</drugstructuredosagenumb>
				<drugstructuredosageunit>003</drugstructuredosageunit>
				<drugseparatedosagenumb>1</drugseparatedosagenumb>
				<drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
				<drugintervaldosagedefinition>804</drugintervaldosagedefinition>
				<drugcumulativedosagenumb>590</drugcumulativedosagenumb>
				<drugcumulativedosageunit>003</drugcumulativedosageunit>
				<drugdosagetext>10 mg, QD</drugdosagetext>
				<drugdosageform>Tablet</drugdosageform>
				<drugadministrationroute>048</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Metastatic renal cell carcinoma</drugindication>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>20120911</drugstartdate>
				<drugenddateformat>102</drugenddateformat>
				<drugenddate>20121108</drugenddate>
				<drugtreatmentduration>59</drugtreatmentduration>
				<drugtreatmentdurationunit>804</drugtreatmentdurationunit>
				<actiondrug>5</actiondrug>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>EVEROLIMUS</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Disease progression</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Disease progression</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not Suspected</drugresult>
				</drugreactionrelatedness>
			</drug>
			<summary>
				<narrativeincludeclinical>Case number PHHO2012CN017597, is an initial report received on 07 Dec 2012, from clinical study CRAD001L2404. This 70-year-old female subject [subject number 20006, centre number 3701] was enrolled in an open-label, multicentre phase II study to examine the efficacy and safety of everolimus as second-line therapy in the treatment of patients with metastatic renal cell carcinoma (RECORD-4).

The subject received the treatment with the study medication RAD at a dose of 10 mg on 11 Sep 2012 and received the last dose on 08 Nov 2012, prior to the event. On 09 Nov 2012, the subject experienced progression of study indication. On 26 Nov 2012, the subject died, due to progression of study indication. It was unknown that autopsy was performed or not. Action taken with the study medication was unknown. The investigator assessed the event as serious (fatal). The investigator reported that the event death was due to progression of concomitant disease  (study indication).

The investigator did not suspect a relationship between the event and the study medication.

Follow up report received on 10 Dec 2012: Updated causality.</narrativeincludeclinical>
				<sendercomment>MR: Concur with the investigator that event progression of study indication was not related to study medication.</sendercomment>
			</summary>
		</patient>
	</safetyreport>
</ichicsr>
